Methods for treating blood disorders with nitric oxide donor compounds
The invention describes methods for treating blood disorders or for treating the symptoms and/or complications associated with blood disorders by administering a therapeutically effective amount of at least one nitric oxide donor compound and optionally at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one therapeutic agent. The antioxidant is preferably a hydralazine compound or a pharmaceutically acceptable salt thereof. The nitric oxide donor compound is preferably N-hydroxy-L-arginine and/or isosorbide dinitrate and/or isosorbide mononitrate. The blood disorder is preferably sickle cell anemia. The complication resulting from a blood disorder is preferably pulmonary hypertension.
1 . A method for treating a blood disorder; treating sickle cell anemia; or treating thalassemia in a patient in need thereof comprising administering a therapeutically effective amount of at least one nitric oxide donor compound.
2 . The method of claim 1 , further comprising administering a therapeutically effective amount of at least one antioxidant and/or at least one therapeutic agent.
3 . The method of claim 1 , wherein the nitric oxide donor compound is N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof.
4 . The method of claim 2 , wherein the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt theereof.
5 . The method of claim 4 , wherein the hydralazine compound is hydralazine hydrochloride.
6 . A method for treating pulmonary hypterension in a patient with sickle cell anemia comprising administering a therapeutically effective amount of at least one nitric oxide donor compound.
7 . The method of claim 6 , further comprising administering a therapeutically effective amount of at least one antioxidant and/or at least one therapeutic agent.
8 . The method of claim 6 , wherein the nitric oxide donor compound is N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof.
9 . The method of claim 7 , wherein the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt theereof.
10 . The method of claim 9 , wherein the hydralazine compound is hydralazine hydrochloride.
11 . A method for treating pulmonary hypterension in a patient with thalassemia comprising administering a therapeutically effective amount of at least one nitric oxide donor compound.
12 . The method of claim 11 , further comprising administering a therapeutically effective amount of at least one antioxidant and/or at least one therapeutic agent.
13 . The method of claim 11 , wherein the nitric oxide donor compound is N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof.
14 . The method of claim 12 , wherein the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt theereof.
15 . The method of claim 14 , wherein the hydralazine compound is hydralazine hydrochloride.
16 . A method for treating systemic systolic hypertension, oxidative stress and/or endothelial dysfunction in patient with sickle cell anemia and/or thalassemia by administering a therapeutically effective amount of at least one nitric oxide donor compound.
17 . The method of claim 16 , further comprising administering a therapeutically effective amount of at least one antioxidant and/or at least one therapeutic agent.
18 . The method of claim 16 , wherein the nitric oxide donor compound is N-hydroxy-L-arginine, isosorbide dinitrate, isosorbide mononitrate or a mixture of two or more thereof.
19 . The method of claim 17 , wherein the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt theereof.
20 . The method of claim 19 , wherein the hydralazine compound is hydralazine hydrochloride.